Women in routine gynecologic care expressed willingness to extend screening intervals and use cytology alone or Pap-HPV cotesting if recommended by a physician.
Conservative management of cervical intraepithelial neoplasia (CIN) grade 2 is an appropriate treatment option for women aged 25 years and younger.
New evidence reveals that there may be a benefit to continuing cervical cancer screening beyond age 65 years.
Women whose cervical cancer screening ceased between ages 50 and 64 years were 6 times more likely than women who were screened to have cervical cancer from ages 65 to 83 years.
A simple blood test using plasma thermogram could serve as an effective new indicator for detecting cervical cancer, including assessment of the cancer’s stage.
A highly specific rapid test for Chlamydia trachomatis has been developed. The best part: the new test requires a direct urine sample only (no total DNA purification needed).
In 4 years, the rate of women receiving breast MRI nearly tripled, but it is underused in women most at risk for breast cancer and overused in women at average risk.
Female providers were twice as likely as their male counterparts to order HPV testing for low-risk women aged 30 to 65 who had normal Pap smear results.
All pregnant women should be tested for diabetes by 13 weeks’ gestation and tested again for gestational diabetes between 24 and 28 weeks’ gestation, say new guidelines.
Breast density laws ensure that women receive critical breast-health information, supporters say, but many of the laws broadly classify breast density and fail to account for varying levels of risk.